Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2014

01.12.2014 | Original Article – Clinical Oncology

Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases

verfasst von: Karin Hohloch, Nick Bertram, Lorenz Trümper, Tim Beissbarth, Frank Griesinger

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Superior vena cava syndrome (SVCS) results from compression of the superior vena cava. SVCS is an emergency requiring immediate diagnosis and treatment. We hypothesized that the outcome of patients (pts.) admitted during regular work hours may differ from that of pts. admitted on weekends.

Methods

From 1992 to 2011, we analyzed all pts. admitted with SVCS due to a malignancy. Clinical outcome was analyzed, focusing on the work-up of pts. hospitalized on a weekend compared with those hospitalized during the week.

Results

One hundred and twenty-four pts. with malignant causes of SVCS were analyzed. Causes were as follows: small cell lung cancer (SCLC) 28.2 %, non-small cell lung cancer 25 %, non-Hodgkin’s lymphoma 25 %, metastasis of other malignant tumors 19.4 % and Hodgkin’s disease 2.4 %. Sixty-five percent of pts. were admitted during the week and 35 % on a weekend. Sixty-one percent received chemotherapy, 24 % radiation, 4 % radiochemotherapy, 9 % palliative treatment and 2 % no treatment at all. No difference in choice of treatment between pts. admitted on a weekday versus weekend was seen. Response was as follows: 7 pts. complete remission, 20 pts. partial response, 38 pts. progressive disease, 3 pts. NC and 15 pts. died. Overall response rate was as follows: Hodgkin’s disease 100 %, non-Hodgkin’s lymphoma 29 %, SCLC 22.8 %, non-small cell lung cancer 9.6 % and metastatic cancer 16.6 %. Only 2 of the 34 pts. with relapsing carcinoma responded. None of the pts. died due to SVCS.

Conclusion

The outcome of pts. with SVCS is not dependent on the day of admission (weekend or weekday) but is related to underlying disease in the setting of a tertiary care center.
Literatur
Zurück zum Zitat Abner A (1993) Approach to the patient who presents with superior vena cava obstruction. Chest 103:394S–397SPubMedCrossRef Abner A (1993) Approach to the patient who presents with superior vena cava obstruction. Chest 103:394S–397SPubMedCrossRef
Zurück zum Zitat Ahmann FR (1984) A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 2:961–969PubMed Ahmann FR (1984) A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 2:961–969PubMed
Zurück zum Zitat Christian E, Adamietz IA, Willich N, Schafer U, Micke O, German Working Group Palliative R, German Society for Radiation O (2008) Radiotherapy in oncological emergencies—final results of a patterns of care study in Germany, Austria and Switzerland. Acta Oncol 47:81–89. doi:10.1080/02841860701481554 PubMedCrossRef Christian E, Adamietz IA, Willich N, Schafer U, Micke O, German Working Group Palliative R, German Society for Radiation O (2008) Radiotherapy in oncological emergencies—final results of a patterns of care study in Germany, Austria and Switzerland. Acta Oncol 47:81–89. doi:10.​1080/​0284186070148155​4 PubMedCrossRef
Zurück zum Zitat Gwon DI, Ko GY, Kim JH, Shin JH, Yoon HK, Sung KB (2013) Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology 266:979–987. doi:10.1148/radiol.12120517 PubMedCrossRef Gwon DI, Ko GY, Kim JH, Shin JH, Yoon HK, Sung KB (2013) Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology 266:979–987. doi:10.​1148/​radiol.​12120517 PubMedCrossRef
Zurück zum Zitat Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF (1997) Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8:781–788PubMedCrossRef Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF (1997) Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8:781–788PubMedCrossRef
Zurück zum Zitat Rowell NP, Gleeson FV (2001) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev CD001316. doi:10.1002/14651858.CD001316 Rowell NP, Gleeson FV (2001) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev CD001316. doi:10.​1002/​14651858.​CD001316
Zurück zum Zitat Rowell NP, Gleeson FV (2002) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol 14:338–351CrossRef Rowell NP, Gleeson FV (2002) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol 14:338–351CrossRef
Zurück zum Zitat Tanigawa N et al (1998) Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 39:669–674PubMedCrossRef Tanigawa N et al (1998) Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 39:669–674PubMedCrossRef
Metadaten
Titel
Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases
verfasst von
Karin Hohloch
Nick Bertram
Lorenz Trümper
Tim Beissbarth
Frank Griesinger
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1764-6

Weitere Artikel der Ausgabe 12/2014

Journal of Cancer Research and Clinical Oncology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.